Literature DB >> 9868673

Coccidioidomycosis in Arizona: increase in incidence from 1990 to 1995.

N M Ampel1, D G Mosley, B England, P D Vertz, K Komatsu, R A Hajjeh.   

Abstract

The number of cases of coccidioidomycosis (incidence) reported to the Arizona Department of Health Services increased from 255 (7.0 per 100,000 population) in 1990 to 623 (14.9 per 100,000 population) in 1995 (P < .001). Four counties in the south central region of the state, which contained 80% of the state's population, had the largest increase and accounted for 95% of all cases in 1995. Cases in persons aged 65 years or older and men were reported more frequently (for both, P < .001). During 1995, 890 patients were discharged from Arizona hospitals with a diagnosis of coccidioidomycosis. Rates of hospitalization were greater among persons aged 55 years or older, men, and African-American (for all three, P < .01). Of the hospitalized patients, 48 died, and 12 (25%) of these patients had a concurrent diagnosis of human immunodeficiency virus infection. These data demonstrate that coccidioidomycosis is a growing health problem in Arizona.

Entities:  

Mesh:

Year:  1998        PMID: 9868673     DOI: 10.1086/515044

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  An archived lot of coccidioidin induces specific coccidioidal delayed-type hypersensitivity and correlates with in vitro assays of coccidioidal cellular immune response.

Authors:  Neil M Ampel; Richard F Hector; Christina P Lindan; George W Rutherford
Journal:  Mycopathologia       Date:  2006-02       Impact factor: 2.574

2.  Preliminary evaluation of whole-blood gamma interferon release for clinical assessment of cellular immunity in patients with active coccidioidomycosis.

Authors:  Neil M Ampel; Daniel K Nelson; Suzette Chavez; Kathryn A Naus; Amanda B Herman; Lijin Li; Keira A Simmons; Demosthenes Pappagianis
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

Review 3.  Coccidioidomycosis in African Americans.

Authors:  Barbara E Ruddy; Anita P Mayer; Marcia G Ko; Helene R Labonte; Jill A Borovansky; Erika S Boroff; Janis E Blair
Journal:  Mayo Clin Proc       Date:  2011-01       Impact factor: 7.616

4.  Rapid identification of dimorphic and yeast-like fungal pathogens using specific DNA probes.

Authors:  M D Lindsley; S F Hurst; N J Iqbal; C J Morrison
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

5.  Modeling valley fever (coccidioidomycosis) incidence on the basis of climate conditions.

Authors:  Korine N Kolivras; Andrew C Comrie
Journal:  Int J Biometeorol       Date:  2003-01-15       Impact factor: 3.787

Review 6.  Coccidioidomycosis: host response and vaccine development.

Authors:  Rebecca A Cox; D Mitchell Magee
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  In vitro whole-blood analysis of cellular immunity in patients with active coccidioidomycosis by using the antigen preparation T27K.

Authors:  Neil M Ampel; Larissa A Kramer; Lijin Li; Deborah S Carroll; Kathleen M Kerekes; Suzanne M Johnson; Demosthenes Pappagianis
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

8.  Pyo-mediastinitis: A complication of pulmonary coccidioidomycosis.

Authors:  Mohamed Y Rady; Arturo Lopez; Bhavesh M Patel; Joel S Larson
Journal:  Can J Infect Dis       Date:  2003-05

9.  Disseminated Coccidioidomycosis with Clinically Evident Splenomegaly in an Immunocompetent Host, First Case Reported in the literature.

Authors:  Garrett R Bird; Robert D Libke; John F Billelo; Nancy A Parks; John S Pollard
Journal:  Mcgill J Med       Date:  2009-11-16

10.  Increasing incidence and severity of coccidioidomycosis at a naval air station.

Authors:  Rachel Lee; Nancy Crum-Cianflone
Journal:  Mil Med       Date:  2008-08       Impact factor: 1.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.